FDA Approves Supplemental Application for Strattera by Lilly
The FDA has approved a supplemental application for Strattera (atomoxetine hydrochloride) submitted by Lilly.
Asset / Drug
Drug and asset intelligence for Strattera with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.